glp 1 approved for sleep apnea Ozempic and apnea: What the new GLP-1 research shows GLP-1 Receptor Agonists at the

However, discontinuation often leads to weight regain and loss of cardiometabolic benefits, 42 , 87 suggesting that, as with traditional antihypertensive drugs, sustained BP control may require ongoing use

Transpl Proc

2013b;36:498504

Orforglipron (LY3502970), a novel, oral nonpeptide glucagonlike peptide1 receptor agonist: a Phase 1a, blinded, placebocontrolled, randomized, singleand multipleascendingdose study in healthy participants

Do not stop taking prescribed medications without medical advice

Patients should never initiate treatment without an in-depth discussion with their primary care physician or an endocrinologist